Rejected from Cell Death and Disease? Where to Submit Next
A post-rejection route map for Cell Death and Disease manuscripts, focused on disease mechanism, functional validation, Springer Nature transfer logic, and next-journal fit.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Cell Death & Disease at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- Cell Death & Disease's scope and readership determine whether the journal is a useful target.
- Scope specificity matters more than headline metrics for most manuscript decisions.
- Selectivity at this journal means fit and framing determine most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope, borderline fit rarely improves after submission.
- If timeline matters: Cell Death & Disease takes Editorial screening first. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
Quick answer: If you were rejected from Cell Death and Disease, decide whether the problem was weak disease mechanism, descriptive cell-death phenotyping, missing functional validation, insufficient in-vivo or patient evidence, overclaimed translational relevance, or transfer-route fit. Cell Death Discovery, Cell Death and Differentiation, Apoptosis, Cell Communication and Signaling, Oncogene, BMC Biology, Scientific Reports, or a disease-specific journal can each be the next route, but only if the manuscript's evidence matches that route.
Do not submit the same file unchanged. Run a Cell Death and Disease rejection fit check before retargeting. For sibling context, see the Cell Death and Disease submission guide, Cell Death and Disease submission process, rejected from Cell Death and Differentiation, and the Cell Death and Disease journal profile.
From our manuscript review practice
After Cell Death and Disease rejection, the next journal should be chosen by the failure mode: disease mechanism, functional validation, transfer fit, or overclaimed translational relevance.
How was this Cell Death and Disease rejection guide checked?
We reviewed Cell Death and Disease author guidance and editorial-process pages, the Springer Nature transfer route, Cell Death Discovery guidance, Cell Death and Differentiation scope pages, nearby cell-death journals, and Manusights pre-submission review patterns for apoptosis, necroptosis, pyroptosis, ferroptosis, autophagy, tumor biology, neurodegeneration, immune cell death, and cardiovascular-disease manuscripts.
Source boundary: Nature Portfolio and Springer Nature own the official Cell Death and Disease scope, guide to authors, editorial process, transfer options, publication policies, and current submission instructions. Manusights interpretation below applies those public facts to post-rejection routing: whether the manuscript is disease-mechanism work, stronger basic cell-death biology, sounder Cell Death Discovery work, broad molecular biology, or a narrower disease-specific study.
Source limitation: public journal pages do not reveal private editor notes, reviewer identities, or an author-specific rejection probability. This page does not claim access to private editorial decisions. It translates public scope and process facts into a retargeting decision after the rejection has already happened.
Concrete source anchors used in this page: Cell Death and Disease positions itself around cell death in disease contexts, its author-facing materials emphasize disease relevance and policy readiness, and its submission route is the Nature system at https://mts-cddis.nature.com/cgi-bin/main.plex.
The local requirements guide records an 8 to 15 pages article-length expectation for Cell Death and Disease research articles. Nature's current open-access page lists the Cell Death and Disease original research and review APC at £3550 / $5250 / €4190, while the closest family alternative, Cell Death Discovery, lists £2290 / $2790 / €2490.
Springer Nature can route rejected manuscripts through transfer support when another journal is a better match. Cell Death Discovery is the closest family route for sounder or narrower cell-death medicine work, while Cell Death and Differentiation is usually a stronger basic-mechanism target rather than a fallback.
What do we see in rejected Cell Death and Disease papers?
In our pre-submission review work on rejected Cell Death and Disease papers, the strongest retargeting signal is whether the manuscript proves a disease-linked cell-death mechanism or only describes a cell-death-associated phenotype. We review the title, abstract, disease model, cell-death assay panel, genetic or pharmacological perturbation, rescue experiment, in-vivo or patient evidence, mechanism figure, data availability, limitation paragraph, and cover letter together. That combined check matters because Cell Death and Disease rejection often exposes a gap between cell-death signal and disease mechanism.
Evidence basis: Manusights submission analysis points to a specific rejection pattern that public instructions only partly reveal. Authors often overstate translational relevance from a single cell line, tumor model, injury model, or marker panel. An anonymized case example is a ferroptosis paper with strong marker expression but no rescue, no disease-relevant validation, and a conclusion that implies therapeutic direction. That paper may need Cell Death Discovery, Apoptosis, or a disease-specific journal unless the mechanism is repaired.
Cell Death and Disease mechanism is marker-based, not causal. The manuscript measures cleaved caspase, LC3, GPX4, TUNEL, PI uptake, or inflammatory markers but does not show causal control of the cell-death pathway. Inspect the abstract, figure sequence, perturbation experiment, rescue data, and conclusion.
Disease relevance is asserted after the biology. Some rejected papers show a plausible death pathway but connect it to disease only in the final discussion. For Cell Death and Disease, the disease model should organize the manuscript early.
Transfer route is misread. Cell Death and Disease is not simply a lower-pressure version of Cell Death and Differentiation. If the work is basic mechanism with little disease context, Cell Death and Differentiation or another molecular-cell-biology route may be cleaner. If the work is sound but narrower, Cell Death Discovery may be better.
Functional validation is thinner than the claim. A pharmacological inhibitor alone rarely settles mechanism. Reviewers often expect genetic knockdown, knockout, rescue, orthogonal assay, dose logic, or disease-model validation when claims are strong.
Translational language outruns the evidence. The cover letter and conclusion may say therapeutic target, biomarker, clinical relevance, or patient benefit before the data justify that claim. The next submission should narrow or support that language.
Check which rejection pattern your Cell Death and Disease paper fits →
Ranked next-journal alternatives
Use this comparison as a cascade, not as a prestige ladder.
Journal | Best fit after Cell Death and Disease rejection | Route logic | Watch before submitting |
|---|---|---|---|
Cell Death Discovery | Sound, narrower cell-death and medicine work | Natural family route when the paper is credible but not Cell Death and Disease-level | Still needs technical soundness and disease relevance |
Cell Death and Differentiation | Stronger basic cell-death or differentiation mechanism | Use only if mechanism is the protagonist | Disease-applied framing may be secondary |
Apoptosis | Programmed cell-death mechanism with basic or clinical orientation | Good for focused apoptosis or related death-pathway work | Match the death modality clearly |
Cell Communication and Signaling | Signaling pathway that explains cell-death regulation | Good when signaling mechanism owns the paper | Do not bury disease relevance |
Oncogene | Cancer mechanism with cell-death pathway relevance | Strong when tumor biology is the true center | Needs cancer-mechanism breadth |
BMC Biology | Broad biology result with sound mechanism but less Cell Death and Disease-specific fit | Good when the work is general biology | Needs broad conceptual framing |
Scientific Reports | Technically sound, narrower study after claim-lowering | Useful when evidence is solid but not selective enough | Avoid overclaiming novelty or therapy |
How should you choose after a Cell Death and Disease rejection?
Start with the rejection reason. If Cell Death and Disease rejected the manuscript because the disease connection was weak, do not submit unchanged to Cell Death Discovery or Scientific Reports while keeping the same disease claim. Either repair the disease model or lower the claim. If the rejection says the paper is too basic, decide whether Cell Death and Differentiation, Apoptosis, or a signaling journal better matches the mechanism. If the paper is sound but narrow, Cell Death Discovery can be a reasonable route.
The tradeoff is practical. Cell Death Discovery can fit sound cell-death medicine work, but it will not fix missing controls. Cell Death and Differentiation can fit stronger basic mechanism, but it is usually a harder target, not a fallback. Apoptosis is better when the death modality is central. Oncogene is better when cancer mechanism owns the work. Scientific Reports can work for a sound narrower study, but only after therapeutic or disease claims are made proportionate.
Use a transfer only when the receiving journal matches the repaired paper. Choose a lateral route when the editor signal says the science is credible but not Cell Death and Disease-shaped. Revise first when reviewers questioned mechanism, model choice, disease relevance, statistics, or validation. Appeal only for a documented factual or process error.
Which alternative fits each rejection reason?
Rejection reason | Best next action | Why |
|---|---|---|
Cell-death signal is descriptive | Add causal perturbation or lower the claim | Another reviewer will flag marker-only biology |
Disease relevance is weak | Repair model, patient link, or disease framing | The next journal still needs pathophysiological meaning |
Basic mechanism dominates | Retarget to Cell Death and Differentiation, Apoptosis, or signaling venues | Disease-applied framing may be wrong |
Translational claim overreaches | Remove therapy language or add validation | Overclaiming follows the paper to every venue |
Transfer offered | Accept only if the receiving journal fits | Transfer speed is not fit by itself |
Route decision | Choose this path when | Do before acting |
|---|---|---|
Transfer | The suggested destination matches the repaired manuscript | Update abstract, cover letter, and limitations |
Lateral move | The work is sound but not Cell Death and Disease-shaped | Pick the journal whose reader values the actual center |
Revise first | Mechanism, disease model, or validation was criticized | Fix the manuscript before any upload |
Appeal | There is documented factual or process error | Appeal once, narrowly, with evidence |
Move on | The same version would repeat the same critique | Rebuild the evidence chain first |
What should you do in the next 48 hours?
First, tag each decision comment as disease fit, cell-death mechanism, validation, model choice, translational overreach, statistics, reporting, or writing. Second, read the abstract, first figure, death-assay panel, perturbation experiment, disease-model result, and cover letter together. If the manuscript needs the cover letter to explain why it is disease-relevant, revise before retargeting. Third, decide whether the paper is Cell Death Discovery-shaped, Cell Death and Differentiation-shaped, Apoptosis-shaped, signaling-shaped, cancer-mechanism work, or a broader biology paper.
The strongest retargeting memo is short:
Question | Answer before choosing the next journal |
|---|---|
What did the rejection actually criticize? | Fit, mechanism, validation, novelty, disease model, claims, or reporting |
What is the manuscript's real center now? | Disease mechanism, basic cell-death biology, cancer mechanism, pathway signaling, or broad biology |
What must change before resubmission? | Abstract, title, figure order, rescue experiment, model framing, cover letter, or claim scope |
What should not be repeated? | Same therapeutic language, same marker-only claim, same unsupported disease conclusion |
Run a Cell Death and Disease rejection and retargeting check →
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
Resubmission checklist
Factor | Question to answer | Why it matters |
|---|---|---|
Disease model | What disease process does the death pathway explain? | Keeps fit visible |
Mechanism | What causal experiment proves pathway control? | Avoids marker-only framing |
Validation | Which orthogonal assay, rescue, animal, or patient evidence supports the claim? | Raises reviewer confidence |
Claim scope | Does the conclusion match the evidence level? | Prevents repeated overclaiming |
Route fit | Which journal values this exact center of gravity? | Avoids another mismatch |
Submit If
Submit to the next journal when... | Think twice before resubmitting if... |
|---|---|
The next journal matches the repaired manuscript's disease-mechanism center | You are using Scientific Reports or Cell Death Discovery only to avoid fixing mechanism |
Cell-death markers, functional validation, model choice, and disease claim are aligned | The same marker-only death claim remains in the abstract |
The cover letter states the disease mechanism without overstating therapeutic readiness | The manuscript's disease relevance appears only in the introduction and final paragraph |
The decision letter has been separated into fit problems and evidence problems | The next target is chosen only because it looks less selective |
Think Twice If
- The rejection challenged mechanism, but the next version changes only the journal name.
- The disease model is still decorative rather than central to the claim.
- The cover letter promises therapy, biomarker value, or patient benefit that the figures do not prove.
- The transfer suggestion is treated as automatic fit instead of a route to evaluate.
Evidence boundary
This page is a post-rejection routing guide, not an official Cell Death and Disease policy page. Official Nature Portfolio and Springer Nature pages control the journal instructions, transfer routes, and policy requirements. Manusights adds the author-side decision layer: whether the rejected manuscript should be repaired for the same disease-mechanism promise, moved to Cell Death Discovery, reframed toward Cell Death and Differentiation or Apoptosis, routed by cancer or signaling logic, or narrowed for a broader technical-soundness journal.
Frequently asked questions
Choose by rejection reason. Cell Death Discovery, Cell Death and Differentiation, Apoptosis, Cell Communication and Signaling, Oncogene, BMC Biology, Scientific Reports, or a disease-specific biology journal can each fit different rejected Cell Death and Disease manuscripts.
Yes if the decision exposed descriptive cell-death data, weak disease relevance, missing functional validation, insufficient in-vivo or patient evidence, or a mismatch between basic mechanism and disease framing.
Appeal only for a clear factual or process error. Most decisions are better handled by repairing the disease-mechanism story or choosing a better-fit Springer Nature or specialist route.
Accept a transfer only if the destination journal matches the repaired manuscript. Cell Death Discovery may fit sounder or narrower work; Cell Death and Differentiation may fit stronger basic mechanism.
Spend 48 hours mapping the decision, then revise the abstract, disease model, functional experiments, mechanism figure, limitations, and cover letter before sending the manuscript anywhere.
Sources
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Your manuscript is never used to train any model.